BioCancell Therapeutics, Inc. (BICL) - Financial and Strategic SWOT Analysis Review by GlobalData

VIEWS: 14 PAGES: 35

More Info
									            BioCancell Therapeutics, Inc. (BICL) - Financial and Strategic SWOT
                                     Analysis Review
        Reference Code: GDPH137411FSA                                                                                         Publication Date: AUG 2012

          Beck Science Center, 8 Hartom St,                  Phone              +972 2 5486555                  Revenue          10.72 (million ILS)
          Har Hotzvim, Jerusalem                             Fax                +972 2 5486550                  Net Profit       -17.48 (million ILS)
          97775                                              Website            www.biocancell.com              Employees        NA
                                                                                BICL [Tel Aviv Stock                             Pharmaceuticals           &
          Israel                                             Exchange                                           Industry
                                                                                Exchange]                                        Healthcare

       Company Overview
       BioCancell Therapeutics, Inc. (BioCancell) is a biotechnology company. It focuses on the identification, development and
       commercialization of therapies to diagnosis and treat cancer-related diseases such as superficial bladder carcinoma, pancreatic
       cancer and ovarian cancer. The company's product pipeline candidates comprise BC-819 and BC-821 evaluated to treat bladder
       cancer, ovarian cancer and pancreatic cancer. The patented, personalized cancer therapy approach of BioCancell is based on
       the identification of target oncogenes, such as H19. It operates along with its subsidiary, namely, BioCancell Therapeutics Israel
       Ltd.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      BioCancell Therapeutics, Inc., SWOT Analysis
         Avraham Hochberg, Ph.D.             Chief Scientific Officer                 Strengths                              Weaknesses
         Aviv Boim                           Director
                                                                                      Orphan Drug Designation                Decline in Liquidity Reserves
         Hanoch Rappaport                    Director
                                                                                      BioCancell's Technology                History of Losses
         Ofer Goldberg                       Director
         David Schlachet                     Director
        Source: Annual Report, Company Website, Primary and Secondary
                                                                                      Opportunities                          Threats
        Research, GlobalData
                                                                                      Fast Track Designation – BC-           Uncertain R&D Outcomes
       Share Data                                                                     819
                                                                                                                             Tightening Government
         BioCancell Therapeutics, Inc.
                                                                                      Changing Demographics                  Regulations
        Share Price (ILS) as on 23-Aug-                                  0.57
        2012
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        EPS (ILS)                                                       -0.66        GlobalData
        Market Cap (million ILS)                                           30
        Enterprise Value (million ILS)                                     42
        Shares Outstanding (million)                                       39
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      May 09, 2012         BioCancell Therapeutics Reports Q1 2012
                                                                                                           Results
                                                                                      Mar 28, 2012         BioCancell Therapeutics Reports 2011 Results
                                                                                      Nov 07, 2011         BioCancell Therapeutics Reports Q3 2011
                                                                                                           Results
                                                                                      Aug 11, 2011         BioCancell Therapeutics Reports Q2 2011
                                                                                                           Results
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData

       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




BioCancell Therapeutics, Inc. (BICL) - Financial and Strategic                                                                Reference Code: GDPH137411FSA
SWOT Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 3
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       BioCancell Therapeutics, Inc. - Key Facts .......................................................................................................................................... 5
       BioCancell Therapeutics, Inc. - Key Employees ................................................................................................................................. 6
       BioCancell Therapeutics, Inc. - Key Employee Biographies ............................................................................................................... 7
       BioCancell Therapeutics, Inc. - Major Products and Services ............................................................................................................ 8
       BioCancell Therapeutics, Inc. - Pharmaceutical Pipeline Products Data............................................................................................ 9
          BioCancell Therapeutics, Inc., Pipeline Products by Therapy Area ................................................................................................ 9
          BioCancell Therapeutics, Inc., Pipeline Products by Development Phase.................................................................................... 10
       BioCancell Therapeutics, Inc. - History............................................................................................................................................. 12
       BioCancell Therapeutics, Inc. - Company Statement ....................................................................................................................... 14
       BioCancell Therapeutics, Inc. - Locations And Subsidiaries............................................................................................................. 16
          Head Office ................................................................................................................................................................................... 16
          Other Locations & Subsidiaries ..................................................................................................................................................... 16
       Section 2 – Company Analysis ......................................................................................................................................................... 17
       BioCancell Therapeutics, Inc. - Business Description ...................................................................................................................... 17
       BioCancell Therapeutics, Inc. - SWOT Analysis............................................................................................................................... 18
          SWOT Analysis - Overview........................................................................................................................................................... 18
          BioCancell Therapeutics, Inc. - Strengths ..................................................................................................................................... 18
             Strength - Orphan Drug Designation ......................................................................................................................................... 18
             Strength - BioCancell's Technology .......................................................................................................................................... 18
             Strength - Product Development Pipeline ................................................................................................................................. 18
          BioCancell Therapeutics, Inc. - Weaknesses................................................................................................................................ 18
             Weakness - Decline in Liquidity Reserves ................................................................................................................................ 18
             Weakness - History of Losses ................................................................................................................................................... 19
          BioCancell Therapeutics, Inc. - Opportunities ............................................................................................................................... 19
             Opportunity - Fast Track Designation – BC-819 ........................................................................................................................ 19
             Opportunity - Changing Demographics ..................................................................................................................................... 19
             Opportunity - Market Potential - Oncology ................................................................................................................................ 19
          BioCancell Therapeutics, Inc. - Threats ........................................................................................................................................ 20
             Threat - Uncertain R&D Outcomes ........................................................................................................................................... 20
             Threat - Tightening Government Regulations ........................................................................................................................... 20
             Threat - Increasing Competitive Pressures ............................................................................................................................... 20
       BioCancell Therapeutics, Inc. - Key Competitors ............................................................................................................................. 21
       Section 3 – Company Financial Ratios ............................................................................................................................................. 22
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 22
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 22
       Performance Chart ........................................................................................................................................................................... 23
       Financial Performance...................................................................................................................................................................... 23
       Financial Ratios - Interim Ratios....................................................................................................................................................... 24
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 25
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 26
          BioCancell Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012 ............................................. 26


BioCancell Therapeutics, Inc. (BICL) - Financial and Strategic          
								
To top